Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

en target lesion revascularization (TLR, repeat procedures driven by lack of blood supply).

-- A 32 percent reduction in the risk of TVF compared to TAXUS (10.7 percent for XIENCE V vs. 15.4 percent for TAXUS, p-value=0.04)*.

-- Low rates of stent thrombosis between one and two years, defined as very late stent thrombosis, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.3 percent for XIENCE V and 1.0 percent for TAXUS) and per the SPIRIT III protocol (0.2 percent for XIENCE V and 1.0 percent for TAXUS). The ARC definition of late stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials.

"Today's approval of XIENCE V is a reflection of Abbott's ongoing commitment to bring innovation-driven, leading-edge medical technologies to the people who need them," added Capek. "With one of the largest, most seasoned vascular sales forces in the United States and with the ability to supply more than half the worldwide market, we will begin shipping units of XIENCE V immediately to meet physician demand for this much awaited, next- generation technology."

More About XIENCE V

XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

The XIENCE V drug coated stent will be available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

XIENCE V was launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review for approval by Japan's Ministry of Health, Lab
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 One of the major revolutions taking ... which is the practice of using genomic and other ... individual biology. Personalized diagnostics—laboratory analyses that inform the practice ... lab,s future. This fall, AACC ,s first ever ... in this exciting field and the novel technologies driving ...
(Date:8/1/2014)... 1, 2014 According to a ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 25.16 billion in 2013, which is expected ... a CAGR of 10.4% from 2014 to 2020. ... Increasing demand for accurate early diagnosis ...
(Date:8/1/2014)... Once a decision has been made to ... discuss how to define your tolerance for lowest cost ... Senior Director of Facilities Integration at Fluor Industrial Services, ... Services, and special guest Carrier Li, Director in Global ... they provide an examination of the Conceptual Design process ...
(Date:8/1/2014)... 2014 Cambrex Corporation (NYSE: CBM ) ... Highlights , Second quarter sales ... same period last year. , Second quarter EBITDA increased ... same period last year (see table at the end of ... excluding the impact of foreign currency, to between 13% and ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16
... 28 /PRNewswire-FirstCall/,-- Evotec AG (Frankfurt Stock Exchange: EVT) ... year ended December 31, 2007., Financial results ... in the,Company,s clinical pipeline and four major corporate ... Technologies (ET), the sale of,the Chemical Development Business ...
... CHAMPAIGN, Ill. Finding a simple and convenient ... identification has been an elusive goal. With current ... ratio too poor, sample preparation too complex or ... service., Now, researchers at the University of Illinois ...
... March 27 Local biotechnology leader,MedImmune announced ... Yiwei Li,has received the distinguished "MedImmune Advancing ... project. The company sponsored the,Montgomery County science ... and presented the award to recognize the ...
Cached Biology Technology:Evotec Announces Financial Results for 2007 2Evotec Announces Financial Results for 2007 3Evotec Announces Financial Results for 2007 4Evotec Announces Financial Results for 2007 5Evotec Announces Financial Results for 2007 6Evotec Announces Financial Results for 2007 7Evotec Announces Financial Results for 2007 8Femtogram-level chemical measurements now possible, U. of I. team reports 2Seneca Valley High School Student Receives Science Award From MedImmune 2Seneca Valley High School Student Receives Science Award From MedImmune 3
(Date:7/31/2014)... research, supported by the National Science Foundation (NSF), ... uniformly accelerates atmospheric warming, indicating instead that certain ... emit into the atmosphere. , The study, ... , focuses on thermokarst lakes, which occur as ... with melted fresh water, converting what was previously ...
(Date:7/31/2014)... long-term follow-up study (HPV-023; NCT00518336) shows the ... human papilloma virus (HPV) vaccine Cervarix. Women ... followed for more than nine years, and ... 100%. This is the longest follow-up report ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. , ...
(Date:7/31/2014)... of animal models against the highly infectious and virulent ... disease that kills approximately 30,000 Americans annually. The research ... Immunity . , In the study, the vaccine ... toxins produced by C. difficile , as well ... that mimics the human disease, after only two immunizations. ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... CHURCH, Va., Feb. 2 CSC (NYSE: ... 12 contractors awarded a Biometrics Operations and Support Services ... Biometrics Task Force (BTF). The indefinite-delivery/indefinite-quantity (IDIQ) contract covers ... to meet the mission needs of BTF business and ...
... 25 percent of eligible African-American adolescents have received the ... Association for Cancer Research conference on the Science of ... of the treatment and might respond to more education. ... funding research to develop ways to increase the rate ...
... University is tracking the movement of the Redbay Ambrosia beetle, ... may severely affect the production of avocados, a $15 million ... in the United States near Savannah, Ga., in 2002, the ... causing widespread mortality in Redbay trees. Dr. Frank Koch, a ...
Cached Biology News:CSC Awarded Department of Defense Biometrics Contract 2African-Americans aware and accepting, but often do not receive, the HPV vaccine 2Holy guacamole: invasive beetle threatens Florida's avocados 2
...
...
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
N,N'-Methylene-bis-acrylamide, Ultra Pure...
Biology Products: